Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
about
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineTailoring to RB: tumour suppressor status and therapeutic response.Polymorphisms in the DNA repair gene ERCC2/XPD and breast cancer risk: a HapMap-based case-control study among Han Women in a Chinese less-developed areaBCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy.Targeting Nur77 translocation.p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).gef gene expression in MCF-7 breast cancer cells is associated with a better prognosis and induction of apoptosis by p53-mediated signaling pathwayTreatment-induced cell cycle kinetics dictate tumor response to chemotherapyAnalysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancerThe impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis.Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.p53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression.The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis.Prognostic value of bcl-2 expression among women with breast cancer in Libya.Bcl-2 expression and triple negative profile in breast carcinoma.Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer.The effect of immunohistochemically detected p53 accumulation in prognosis of breast cancer; A retrospective survey of outcome.Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.Analysis of the potent prognostic factors in luminal-type breast cancer.The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer.Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
P2860
Q27851827-62133641-78F8-4B26-B623-E2F99326C291Q33338630-F304C926-3089-4E7D-8EC5-13DC9975CECEQ33817285-855F64D0-1FAD-46D3-9B98-69B6F993B52EQ34040108-DEE203B8-6430-4B31-B689-C58E91C7CF32Q34284010-563A7CD9-5F7F-4A39-AEAF-B217F3831FB5Q34491903-D8E51464-CE34-4FF6-B403-1C9DB941ACEBQ34588195-3D223585-2160-4105-80E4-F1E0E35040B5Q35146274-39E81FF0-7192-4918-880F-2E95CDD78787Q35600102-5056F0AB-0D72-4F13-8B24-94DE8BDAF72BQ35740145-C9AA7296-E7A3-4332-BA75-C162BC4F3A8EQ35909551-DF4301E7-403D-4528-92EA-2EFDF5717CFBQ36107330-D6FF8C91-8C1E-4550-A46E-71EFF18046C0Q36609527-463308FC-8469-4924-A4BD-48AECB1F16FDQ36678716-E08ED0C1-7515-4333-9546-50FBB65F9961Q37031974-0080FD5C-C43A-4418-9F00-90799EE6AE31Q37049920-F6C0E52C-146B-48D8-BC98-8D58E2862508Q37549455-EB92497D-BAD4-4DA7-A76E-4CE3263B56E5Q37838167-DE02CAF3-61F8-4262-94DF-DC3B1D26EFBCQ37858457-67CB20AE-DC77-49B2-A54E-0D2BE025CB28Q37993442-57A3CE57-2BFD-4A27-9356-95578C6D0B3BQ38994709-A884DA13-54FD-44B8-8F4D-A150BCF1E244Q39116598-DA364D97-4D7C-40E3-B626-6C86ABD534A9Q39515471-01EEB2F9-2B55-49FB-9D17-5FC48E3C5550Q41236981-110BF3AF-3725-42C0-81D5-1E8BA4A5459FQ42483948-9CA643CD-C50C-49F4-B5A3-5AD33F336B9DQ42701381-748E396F-81E3-45CA-A9C7-CE626B9A276AQ44134114-50E49C49-3A99-4317-B436-C7230209C03DQ50078523-9E098191-4D18-4992-8B0F-71A250257771
P2860
Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Prognostic and predictive effe ...... rimary breast cancer patients.
@ast
Prognostic and predictive effe ...... rimary breast cancer patients.
@en
Prognostic and predictive effe ...... rimary breast cancer patients.
@nl
type
label
Prognostic and predictive effe ...... rimary breast cancer patients.
@ast
Prognostic and predictive effe ...... rimary breast cancer patients.
@en
Prognostic and predictive effe ...... rimary breast cancer patients.
@nl
prefLabel
Prognostic and predictive effe ...... rimary breast cancer patients.
@ast
Prognostic and predictive effe ...... rimary breast cancer patients.
@en
Prognostic and predictive effe ...... rimary breast cancer patients.
@nl
P2093
P1476
Prognostic and predictive effe ...... rimary breast cancer patients.
@en
P2093
Axel R Zander
Claudia Schmoor
Martin Schumacher
Nicolaus Kröger
Thomas Löning
P304
P356
10.1158/1078-0432.CCR-05-1340
P407
P577
2006-01-01T00:00:00Z